The society for immunotherapy of cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

Nature Reviews Clinical Oncology

Volumn 10, Issue 10, 2013, Pages 588-598

  Kaufman, Howard L ^a   Kirkwood, John M ^b   Hodi, F Stephen ^c   Agarwala, Sanjiv ^d   Amatruda, Thomas ^e   Bines, Steven D ^a   Clark, Joseph I ^f   Curti, Brendan ^g   Ernstoff, Marc S ^h   Gajewski, Thomas ⁱ   Gonzalez, Rene ^j   Hyde, Laura Jane ^e   Lawson, David ^k   Lotze, Michael ^b   Lutzky, Jose ^l   Margolin, Kim ^m   McDermott, David F ⁿ   Morton, Donald ^o   Pavlick, Anna ^p   Richards, Jon M ^q   Sharfman, William ^r   Sondak, Vernon K ^s   Sosman, Jeffrey ^t   Steel, Susan ^e   Tarhini, Ahmad ^b   Thompson, John A ^m   Titze, Jill ^a   Urba, Walter ^g   White, Richard ^u   Atkins, Michael B ^v   more..

^a RUSH UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d St Luke's Cancer Center   (United States)

^e Minnesota Oncology ^*  (United States)

^f Loyola University Medical Cente   (United States)

^g Providence Cancer Center   (United States)

^h DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF CHICAGO   (United States)

^j UNIVERSITY OF COLORADO   (United States)

^k EMORY UNIVERSITY   (United States)

^l Mount Sinai Comprehensive Cancer Center   (United States)

^m UNIVERSITY OF WASHINGTON   (United States)

ⁿ BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^o JOHN WAYNE CANCER INSTITUTE   (United States)

^p NEW YORK UNIVERSITY   (United States)

^q ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

^r JOHNS HOPKINS UNIVERSITY   (United States)

^s H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^t VANDERBILT INGRAM CANCER CENTER   (United States)

^u CAROLINAS MEDICAL CENTER   (United States)

^v GEORGETOWN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; B RAF KINASE; DACARBAZINE; INTERLEUKIN 2; IPILIMUMAB; PAROXETINE; PEGINTERFERON ALPHA2B; PEPTIDE VACCINE; PLACEBO; VEMURAFENIB;

AUTOIMMUNE THYROIDITIS; BRAF GENE; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS DEVELOPMENT; CUTANEOUS MELANOMA; DEPRESSION; DOSE RESPONSE; DRUG MEGADOSE; ENDOCRINE DISEASE; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; METASTATIC MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE C KIT; PATIENT ASSESSMENT; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SKIN TOXICITY; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; VITILIGO;

DISEASE MANAGEMENT; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOTHERAPY; MEDICAL ONCOLOGY; MELANOMA; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84885022736     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2013.153     Document Type: Review

References (80)

1. National Cancer Institute. Cancer Trends Progress Report-2011/2012 Update [online], http://progressreport.cancer.gov/index.asp (2012).
2. Garbe, C., Eigentler, T. K., Keilholz, U., Hauschild, A. & Kirkwood, J. M. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16, 5-24 (2011).
3. Balch, C. M. et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27, 6199-6206 (2009).
4. Eggermont, A. M. et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372, 117-126 (2008). (Pubitemid 351952257)
5. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
6. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
7. Atkins, M. B., Kunkel, L., Sznol, M. & Rosenberg, S. A. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J. Sci. Am. 6 (Suppl. 1), S11-S14 (2000).
8. Prieto, P. A. et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin. Cancer Res. 18, 2039-2047 (2012).
9. Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526 (2011).
10. Weber, J. S., Kahler, K. C. & Hauschild, A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30, 2691-2697 (2012).
11. Hoos, A. et al. Improved endpoints for cancer immunotherapy trials. J. Natl Cancer Inst. 102, 1388-1397 (2010).
12. Wolchok, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412-7420 (2009).
13. Graham, R., Mancher, M., Miller Wolman, D., Greenfield, S. & Steinberg, E. (Eds) Clinical practice guidelines we can trust (Institute of Medicine of the National Academies, Washington D. C., 2011).
14. SITC. Cancer Immunotherapy Guidelines [online], http://www.sitcancer.org/ about-sitc/initiatives/cancer-immunotherapy-guidelines (2013).
15. Soong, S. J. et al. Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC melanoma database. Ann. Surg. Oncol. 17, 2006-2014 (2010).
16. Wong, S. L. et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J. Clin. Oncol. 30, 2912-2918 (2012).
17. Grob, J. J. et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 351, 1905-1910 (1998). (Pubitemid 28297445)
18. Hansson, J. et al. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol. 12, 144-152 (2011).
19. Hauschild, A. et al. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate-and high-risk primary melanoma without clinically detectable node metastasis. J. Clin. Oncol. 21, 2883-2888 (2003). (Pubitemid 46621837)
20. Hancock, B. W. et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J. Clin. Oncol. 22, 53-61 (2004). (Pubitemid 41095114)
21. Hauschild, A. et al. Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma. J. Clin. Oncol. 27, 3496-3502 (2009).
22. Hauschild, A. et al. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of = 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. J. Clin. Oncol. 28, 841-846 (2010).
23. Tarhini, A. A., Gogas, H. & Kirkwood, J. M. INF-? in the treatment of melanoma. J. Immunol. 89, 3789-3793 (2012).
24. Kirkwood, J. M. et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14, 7-17 (1996). (Pubitemid 26019991)
25. Kirkwood, J. M. et al. High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J. Clin. Oncol. 18, 2444-2458 (2000). (Pubitemid 30415832)
26. Kirkwood, J. M. et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin. Cancer Res. 10, 1670-1677 (2004). (Pubitemid 38435557)
27. Bottomley, A. et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J. Clin. Oncol. 27, 2916-2923 (2009).
28. Eggermont, A. M. et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur. J. Cancer 48, 218-225 (2012).
29. Hernberg, M., Pyrhonen, S. & Muhonen, T. Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials. J. Immunother. 22, 145-154 (1999). (Pubitemid 29135899)
30. Pirard, D., Heenen, M., Melot, C. & Vereecken, P. Interferon alpha as adjuvant postsurgical treatment of melanoma: a meta-analysis. Dermatology 208, 43-48 (2004). (Pubitemid 38142333)
31. Mocellin, S., Pasquali, S., Rossi, C. R. & Nitti, D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J. Natl Cancer Inst. 102, 493-501 (2010).
32. Hauschild, A. et al. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 112, 982-994 (2008). (Pubitemid 351304581)
33. Kirkwood, J. M. et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol. 19, 2370-2380 (2001). (Pubitemid 32391207)
34. Schuhan, C., Muley, T., Dienemann, H. & Pfannschmidt, J. Survival after pulmonary metastasectomy in patients with malignant melanoma. Thorac. Cardiovasc. Surg. 59, 158-162 (2011).
35. Wasif, N., Bagaria, S. P., Ray, P. & Morton, D. L. Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes. J. Surg. Oncol. 104, 111-115 (2011).
36. Chua, T. C. et al. Surgical management of melanoma lung metastasis: an analysis of survival outcomes in 292 consecutive patients. Ann. Surg. Oncol. 19, 1774-1781 (2012).
37. Howard, J. H. et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first multicenter selective lymphadenectomy trial (MSLT-I). Ann. Surg. Oncol. 19, 2547-2555 (2012).
38. Lee, D. S., White, D. E., Hurst, R., Rosenberg, S. A. & Yang, J. C. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy. Cancer J. Sci. Am. 4, 86-93 (1998). (Pubitemid 29090712)
39. Verdecchia, G. M. et al. Adjuvant adoptive immunotherapy in patients with stage III and resected stage IV melanoma: a pilot study [Italian]. Tumori 89, 298-300 (2003).
40. Saenger, Y. M. & Wolchok, J. D. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun. 8, 1 (2008).
41. Pennock, G. K., Waterfield, W. & Wolchok, J. D. Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: How different are these from conventional treatment responses? Am. J. Clin. Oncol. 35, 606-611 (2012).
42. Rosenberg, S. A. et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin. JAMA 271, 907-913 (1994).
43. Atkins, M. B. et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105-2116 (1999). (Pubitemid 29318842)
44. Wolchok, J. D. et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 11, 155-164 (2010).
45. Trinh, V. A. & Hwu, W. J. Ipilimumab in the treatment of melanoma. Expert Opin. Biol. Ther. 12, 773-782 (2012).
46. Margolin, K. et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 13, 459-465 (2012).
47. Pichert, G., Jost, L. M., Fierz, W. & Stahel, R. A. Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma. Br. J. Cancer 63, 287-292 (1991).
48. Dorval, T., Fridman, W. H., Mathiot, C., Sastre, X. & Pouillart, P. Treatment of metastatic malignant melanoma with interleukin-2 [French]. Bull. Cancer 79, 781-787 (1992).
49. Monig, H., Hauschild, A., Lange, S. & Folsch, U. R. Suppressed thyroid-stimulating hormone secretion in patients treated with interleukin-2 and interferon-alpha 2b for metastatic melanoma. Clin. Investig. 72, 975-978 (1994).
50. Vlasveld, L. T. et al. Phase II study of intermittent continuous infusion of low-dose recombinant interleukin-2 in advanced melanoma and renal cell cancer. Ann. Oncol. 5, 179-181 (1994). (Pubitemid 24062574)
51. Farace, F. et al. Low-dose IL-2 treatment: activation of discrete T-and NK-cell sub-populations in vivo. Int. J. Cancer 62, 523-528 (1995).
52. Fleischmann, M., Celerier, P., Bernard, P., Litoux, P. & Dreno, B. Long-term interferon-alpha therapy induces autoantibodies against epidermis. Dermatology 192, 50-55 (1996). (Pubitemid 26026795)
53. Trehu, E. G. et al. Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera. Clin. Cancer Res. 2, 1341-1351 (1996). (Pubitemid 26299433)
54. McDermott, D. F. et al. A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor. Clin. Cancer Res. 4, 1203-1213 (1998). (Pubitemid 28213331)
55. Schachter, J. et al. Toxicity of adjuvant high-dose interferon-alpha-2b in patients with cutaneous melanoma at high risk of recurrence. Oncol. Rep. 6, 1389-1393 (1999).
56. Fraenkel, P. G. et al. Induction of myasthenia gravis, myositis, and insulin-dependent diabetes mellitus by high-dose interleukin-2 in a patient with renal cell cancer. J. Immunother. 25, 373-378 (2002). (Pubitemid 34857292)
57. Chianese-Bullock, K. A. et al. Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2. J. Immunother. 28, 412-419 (2005). (Pubitemid 40962336)
58. Gogas, H. et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 354, 709-718 (2006). (Pubitemid 43247141)
59. Koon, H. & Atkins, M. Autoimmunity and immunotherapy for cancer. N. Engl. J. Med. 354, 758-760 (2006). (Pubitemid 43247149)
60. Schwartzentruber, D. J. Guidelines for the safe administration of high-dose interleukin-2. J. Immunother. 24, 287-293 (2001). (Pubitemid 32825860)
61. Friebe, A. et al. Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma. Psychosomatics 51, 466-473 (2010).
62. Pizzi, C. et al. Low-dose recombinant IL-2 induces psychological changes: monitoring by Minnesota Multiphasic Personality Inventory (MMPI). Anticancer Res. 22, 727-732 (2002). (Pubitemid 34475221)
63. Weber, J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 12, 864-872 (2007). (Pubitemid 47328229)
64. Capuron, L. et al. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am. J. Psychiatry 160, 1342-1345 (2003). (Pubitemid 41070955)
65. Van Gool, A. R. et al. Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients. Psychiatry Res. 119, 125-132 (2003). (Pubitemid 36829424)
66. Schaefer, M. et al. Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha. Brain Behav. Immun. 18, 555-562 (2004). (Pubitemid 39149775)
67. Bannink, M. et al. Interferon-alpha influences tryptophan metabolism without inducing psychiatric side effects. Neuropsychobiology 55, 225-231 (2007). (Pubitemid 47525244)
68. Miller, R. L. et al. Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma. Cancer Res. 49, 1871-1876 (1989). (Pubitemid 19108419)
69. Musselman, D. L. et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N. Engl. J. Med. 344, 961-966 (2001). (Pubitemid 32240314)
70. Poonacha, T. K. & Go, R. S. Level of scientific evidence underlying recommendations arising from the National Comprehensive Cancer Network clinical practice guidelines. J. Clin. Oncol. 29, 186-191 (2011).
71. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
72. Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134-144 (2013).
73. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012).
74. Topalian, S. L., Drake, C. G. & Pardoll, D. M. Targeting the PD-1/b7-H1 (PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 24, 207-212 (2012).
75. Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133 (2013).
76. Postow, M. A. et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366, 925-931 (2012).
77. Seung, S. K. et al. Phase 1 study of stereotactic body radiotherapy and interleukin-2-tumor and immunologic responses. Sci. Transl. Med. 4, 137-174 (2012).
78. Kaufman, H. L. & Bines, S. D. OPTIM trial: a phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol. 6, 941-949 (2010).
79. Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphosis leukemia. N. Engl. J. Med. 368, 1509-1518 (2013).
80. Burns, W. R. et al. A high molecular-weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Cancer Res. 70, 3027-3033 (2010).